Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED
LEXX logo LEXX
Upturn stock ratingUpturn stock rating
LEXX logo

Lexaria Bioscience Corp (LEXX)

Upturn stock ratingUpturn stock rating
$1.93
Delayed price
upturn advisory
PASS
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

01/14/2025: LEXX (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

Analysis of Past Performance

Type Stock
Historic Profit -28.62%
Avg. Invested days 38
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 01/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 35.95M USD
Price to earnings Ratio -
1Y Target Price 10
Price to earnings Ratio -
1Y Target Price 10
Volume (30-day avg) 237481
Beta 1.06
52 Weeks Range 1.36 - 6.85
Updated Date 01/14/2025
52 Weeks Range 1.36 - 6.85
Updated Date 01/14/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.5

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date 2025-01-10
When After Market
Estimate -0.12
Actual -0.16

Profitability

Profit Margin -
Operating Margin (TTM) -2074.9%

Management Effectiveness

Return on Assets (TTM) -38.21%
Return on Equity (TTM) -70.66%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 27964946
Price to Sales(TTM) 87.47
Enterprise Value 27964946
Price to Sales(TTM) 87.47
Enterprise Value to Revenue 67.37
Enterprise Value to EBITDA -7.22
Shares Outstanding 17452600
Shares Floating 13225553
Shares Outstanding 17452600
Shares Floating 13225553
Percent Insiders 7.03
Percent Institutions 6.08

AI Summary

Lexaria Bioscience Corp. (NASDAQ: LEXX) Stock Overview

Company Profile:

History and Background: Lexaria Bioscience Corp. is a Canadian biotechnology company founded in 1994. The company focuses on developing and commercializing innovative drug delivery platforms. Its main platform technology is DehydraTECH, which improves the bioavailability and absorption of various active pharmaceutical ingredients (APIs) by increasing their water solubility.

Core Business Areas: The company's core business areas include:

  • Developing and licensing DehydraTECH technology for pharmaceuticals, nutraceuticals, and cosmetics.
  • Developing and marketing its own consumer products containing DehydraTECH.
  • Providing contract research and development services to other companies.

Leadership and Corporate Structure: Lexaria's leadership team consists of:

  • Chris Bunka, PhD: Chief Executive Officer (CEO)
  • John Docherty, PhD: Chief Science Officer (CSO)
  • Christopher DeFeo: Chief Legal Officer and General Counsel
  • John Traub: Chief Financial Officer (CFO)
  • Jeffery Yapp: President and Business Development

Top Products and Market Share:

  • Lexaria's top product is DehydraTECH: It is a platform technology that can be used with various API's. The company is currently developing DehydraTECH-based versions of nicotine, CBD, and caffeine. It also has several other APIs in its pipeline.
  • Market share: Lexaria does not currently have a significant market share in the drug delivery or consumer product markets. However, DehydraTECH has the potential to disrupt these markets by improving the effectiveness of various APIs.

Total Addressable Market (TAM):

  • The global drug delivery market was valued at approximately $143.62 billion in 2021 and is expected to reach $257.6 billion by 2028, growing at a CAGR of 9.1%.
  • The global consumer health market was estimated at $786.8 billion in 2021 and is projected to reach $999.5 billion by 2028, growing at a CAGR of 4.4%.

Financial Performance:

  • Lexaria reported revenue of $75,988 in 2019, $154,910 in 2020, and $498,195 in 2021.
  • Net income was negligible in all three years.
  • The company had negative cash flow from operations of $714,311 in 2019, $755,555 in 2020, and $3,951,918 in 2021.
  • Lexaria has a significant cumulative deficit of over $77 million as of 2021.

Dividends and Shareholder Returns:

  • Lexaria does not currently pay dividends.
  • Shareholder returns have been negative due to the company's lack of profits.

Growth Trajectory:

  • Lexaria is a pre-revenue company, and therefore, its historical growth rate is not meaningful.
  • Future growth will depend on the successful development and commercialization of DehydraTECH-based products.
  • Recent product launches and strategic initiatives include the launch of several DehydraTECH-based products in the dietary supplement market. These include nicotine gum, cannabidiol (CBD) sublingual strips, and nicotine pouches.

Market Dynamics:

  • The drug delivery market is highly competitive and fragmented. There are many existing players with established products.
  • The consumer health market is also competitive, with large established players dominating the sector.
  • Technological advancements in drug delivery and consumer health products are ongoing, leading to rapid innovation in the field. Lexaria must keep pace with advancements to ensure its technology remains effective.

Competitors:

  • Key competitors in the drug delivery market include Catalent, Lonza, and AptarGroup.
  • Key competitors in the consumer health market include Pfizer, GSK, and Bayer.

Potential Challenges and Opportunities:

  • Challenges:
    • Obtaining regulatory approval for DehydraTECH-based products in various markets.
    • Demonstrating efficacy and safety of their products to healthcare professionals.
    • Raising additional capital through debt or equity offerings to support their growth strategy.
    • Competing with larger and more established players in the market.
  • Opportunities:
    • DehydraTECH's potential to improve the efficacy and delivery of various APIs can be attractive to pharmaceutical and consumer products companies.
    • The company could form strategic partnerships to accelerate its product development and commercialization efforts.
    • The rapidly growing health and wellness market presents a significant opportunity for DehydraTECH-based products.

Recent Acquisitions:

  • Lexaria has not reported any acquisition activities in the past three years.

AI-Based Fundamental Rating:

A comprehensive analysis and an AI-based fundamental rating are not feasible at this time because the company is pre-revenue.

Sources and Disclaimers:

Sources for analysis and data include the company's website, press releases, SEC filings, and industry articles and reports.

Disclaimer: I am an AI chatbot and cannot provide financial advice. Data analysis and insights offered above should not be considered an endorsement for investment in Lexaria Bioscience Corp.

About NVIDIA Corporation

Exchange NASDAQ
Headquaters Kelowna, BC, Canada
IPO Launch date 2006-10-10
CEO -
Sector Healthcare
Industry Biotechnology
Full time employees 5
Full time employees 5

Lexaria Bioscience Corp. operates as a biotechnology company. It offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules, including glucagon-like peptide-1 drugs (GLP-1) and glucose -dependent insulinotropic polypeptide drugs (GIP), vitamins, pain medications, hormones, phosphodiesterase type 5 (PDE5) inhibitors, antivirals, nicotine and its analogs, and cannabinoids. Its DehydraTECH technology is applied to various therapeutic indications, such as diabetes, weight loss, hypertension, and heart disease; is implemented in a multitude of ingestible or topically administered product formats comprising oral suspensions, tablets, capsules, foods, beverages, creams, lotions, and skin patches; and is suitable for a variety of product formats, including pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The company was formerly known as Lexaria Corp. and changed its name to Lexaria Bioscience Corp. in April 2016. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​